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Abstract Fisetin and hesperetin, flavonoids from various
plants, have several pharmaceutical activities including anti-
oxidative, anti-inflammatory, and anticancer effects. Howev-
er, studies elucidating the role and the mechanism(s) of action
of fisetin and hesperetin in acute promyelocytic leukemia are
absent. In this study, we investigated the mechanism of the
antiproliferative and apoptotic actions exerted by fisetin and
hesperetin on human HL60 acute promyelocytic leukemia
cells. The viability of HL60 cells was evaluated using the
MTT assay, apoptosis by annexin V/propidium iodide (PI)
staining and cell cycle distribution using flow cytometry,
and changes in caspase-3 enzyme activity and mitochondrial
transmembrane potential. Moreover, we performed whole-
genome microarray gene expression analysis to reveal genes
affected by fisetin and hesperetin that can be important for
developing of future targeted therapy. Based on data obtained
from microarray analysis, we also described biological net-
works modulated after fisetin and hesperetin treatment by
KEGG and IPA analysis. Fisetin and hesperetin treatment
showed a concentration- and time-dependent inhibition of
proliferation and induced G2/M arrest for both agents and
G0/G1 arrest for hesperetin at only the highest concentrations.
There was a disruption of mitochondrial membrane potential
together with increased caspase-3 activity. Furthermore,
fisetin- and hesperetin-triggered apoptosis was confirmed by
annexin V/PI analysis. The microarray gene profiling analysis
revealed some important biological pathways including
mitogen-activated protein kinases (MAPK) and inhibitor of
DNA binding (ID) signaling pathways altered by fisetin and
hesperetin treatment as well as gave a list of genes modulated
≥2-fold involved in cell proliferation, cell division, and apo-
ptosis. Altogether, data suggested that fisetin and hesperetin
have anticancer properties and deserve further investigation.
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Introduction
Acute promyelocytic leukemia (APL), a distinct variant of
acute myeloid leukemia (AML), is different from other types
of AML with its molecular biology and clinical outcomes.
APL is characterized by abnormal accumulation of immature
granulocytes (promyelocytes) in the bone marrow and blood
stream [1]. In the majority of APL cases, translocation,
t(15;17), between the retinoic acid receptor-alpha (RARα)
gene on chromosome 17 and the promyelocytic leukemia
(PML) gene on chromosome 15 is very common, which is
responsible for the pathogenesis of APL [2]. Even though
several treatment strategies are available for APL such as che-
motherapy including all-trans retinoic acid (ATRA) and arse-
nic trioxide (ATO) and stem cell transplantation, they remain
incurable due to their heterogenic nature, differences in their
biological characteristics, drug resistance, and high recurrence
rate and harmful side effects [3]. Thus, efforts to develop new
treatments for APL are necessary.
Recently, dietary phytochemicals targeting cellular path-
ways in tumor cells have comprised great interest to develop
novel apoptosis-based therapies [4]. Of these phytochemicals,
flavonoids widely distributed in plants have received
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increasing attention for their potential chemopreventive role,
because they have been known to impair cancer cell growth
by modulating various signaling pathways involved in differ-
ent stages of cancer development as well as inducing apopto-
sis [5].
Fisetin (3,3′,4′,7-tetrahydroxyflavone), a bioactive flavanol
molecule, is found in various fruits and vegetables, such as
strawberry, apple, persimmon, grape, onion, and cucumber
[6]. Fisetin has a broad range of biological activities including
antioxidant, anti-inflammatory, and anticancer effects, and its
chemotherapeutic potential has been studied on various
in vitro and in vivo cancer models [7]. Despite that fisetin
has been shown to induce apoptosis in a variety of cell lines,
fisetin-mediated antiproliferative and apoptotic effects were
specific for cancer cells based on differential modulation of
cellular signaling pathways. The mechanisms behind fisetin’s
actions include induction of cell cycle arrest by altering cell
cycle regulators [8], inhibition of signaling pathways such as
NF-κB and PI3K/Akt pathways [9, 10], prevention of cell
invasion and metastasis [11], and modulation of apoptotic
and anti-apoptotic molecules [12]. These effects of fisetin
have been evaluated on various cancer types such as colon,
prostate, pancreas, and lung cancers; however, there is no
study investigating the underlying mechanism(s) of fisetin in
APL.
Citrus species have attracted significant attention for their
flavonoid content which is thought to be promising in cancer
therapy. Hesperidin and hesperetin are the most important
examples of these flavonones found in citrus fruits such as
lemon and orange with a wide range of pharmacological prop-
erties including antioxidant, anti-inflammatory, and anticancer
effects [13]. Hesperidin could be considered as a pro-drug,
since it is metabolized to hesperetin before absorption [14].
Promising results derived from a noticeable body of evidence
displayed that hesperetin could mediate its anticancer effects
in several cancer types by affecting several cellular targets.
Some of these mechanisms include modulation of apoptotic
proteins [15], increased activity of several caspases like
caspase-3 and caspase-9 [16], and arrest of cell cycle progres-
sion [17]. On the other hand, the mechanism(s) responsible for
the biological effects of hesperetin in APL cells remain un-
identified yet.
The present study was undertaken to determine the molec-
ular mechanism of fisetin- and hesperetin-induced cell death
in HL60 APL cells by investigating their effects on cell pro-
liferation, apoptosis, caspase-3 enzyme activity, loss of mito-
chondrial membrane potential, and cell cycle distribution.
Moreover, whole-genome microarray analysis was performed
to establish affected genes and genetic networks in response to
fisetin and hesperetin. This is the first report that demonstrates
the therapeutic potential of these flavanoids in APL cells via
inducing apoptosis and cell cycle arrest and modulating mul-
tiple cellular targets.
Materials and methods
Chemicals
Fisetin (purity ≥98 %) and hesperetin (purity ≥95 %) were
obtained from Santa Cruz Biotechnology, Inc. (Heidelberg,
Germany). Ten-millimolar stock solutions of these agents
were prepared in DMSO and stored at −20 °C. The final con-
centration of DMSO did not exceed more than 0.1 % in cul-
ture. Penicillin-streptomycin, RPMI 1640, and fetal bovine
serum were obtained from Invitrogen (Paisley, UK). MTT
reagent was purchased from Sigma (St. Louis, MO).
Cell culture
Human HL60 APL cells were kindly provided by Dr. Ali
Ugur Ural from the Hematology Department of Gulhane
Medical School, cultured in RPMI 1640 growth medium sup-
plemented with 10 % fetal bovine serum and 1 % penicillin-
streptomycin at 37 °C in 5 % CO2.
MTTassay
Antiproliferative effects of fisetin and hesperetin on HL60
cells were assessed by the MTTcell proliferation assay, which
depends on reduction ofMTT dye to its insoluble formazan by
NAD(P)H-dependent cellular oxidoreductase enzymes, giv-
ing a purple color in living cells. Briefly, 1×104 cells grown
in 96-well plates were exposed to increasing concentrations of
fisetin and hesperetin (1–200 μM) for 48 and 72 h. These cells
were then incubated with 20 μl MTT for 3 h, and the resulting
formazan crystals were dissolved in 100 μl DMSO. The ab-
sorbance values were read at 570-nm wavelength with an
ELISA reader (Thermo Electron CorporationMultiskan Spec-
trum, Finland). Finally, the IC50 value (drug concentration
which inhibits cell growth by 50 %) of these agents was cal-
culated from cell proliferation plots.
Assessment of apoptosis in human HL60 cells by annexin
V-FITC/PI double staining
To examine apoptotic effects of fisetin and hesperetin on APL
cells, the movement of phosphatidylserine (PS) from the inner
leaflet of the membrane to the outer leaflet can be easily de-
tected by using a fluorescent conjugate of annexin V (Annexin
V-FITC Apoptosis Detection Kit, BioVision Research Prod-
ucts, USA). A total of 5×105 cells/well seeded into six-well
plates were treated with increasing concentrations of agents
for 72 h. Then, the collected cells were washed twice with cold
PBS, suspended with 200 μl of 1× binding buffer, and stained
with 2 μl of FITC Annexin V and 2 μl of propidium iodide
(PI) for 15 min at room temperature in the dark. Afterwards,
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samples were analyzed by flow cytometry (BD Facscanto
Flowcytometry, Belgium) within 1 h.
Detection of the changes in mitochondrial membrane
potential
The effects of fisetin and hesperetin on mitochondrial mem-
brane potential (MMP) of HL60 cells were examined by JC-1
Mitochondrial Membrane Potential Detection Kit (Cayman
Chemicals, USA), which uses a unique cationic dye, JC-1.
JC-1 has the ability to enter into mitochondria and change its
color from green to red reversibly. In healthy cells with high
MMP, JC-1 spontaneously forms complexes in mitochondria
and gives intense red fluorescence. On the other hand, in ap-
optotic cells with low MMP, JC-1 remains in the monomeric
form and gives green fluorescence. Briefly, 5×105 cells/well
seeded into six-well plates were treated with agents for 72 h
and then collected by centrifugation at 180g for 10 min. The
pellets were homogenized with 300 μl medium containing
30 μl of JC-1 dye and incubated at 37 °C in 5 % CO2 for
30 min. Then, the cells were collected by centrifugation at
400g for 5 min and homogenized with 200 μl assay buffer.
Afterwards, 100 μl from each sample was added to a 96-well
plate as triplicates. In healthy cells, the aggregate red form has
absorption/emission maxima of 560/595 nm, whereas in apo-
ptotic cells, the monomeric green form has absorption/
emission maxima of 485/535 nm, which were read by a fluo-
rescence ELISA reader (Thermo Varioskan Spectrum, Fin-
land). The ratio of fluorescent intensity of JC-1 monomers
(green) to fluorescent intensity of JC-1 aggregates (red) was
calculated for each concentration as well as for the untreated
control sample.
Measurement of caspase-3 activity
Changes in caspase-3 activity of the cells were examined by
caspase-3 colorimetric assay kit (BioVision Research Prod-
ucts, USA), which is based on spectrophotometric detection
of the chromophore p-nitroanilide (pNA) released from the
labeled substrate DEVD-pNA after cleavage by caspases.
Briefly, the cells (5×105 cells/well seeded into six-well plates)
induced to undergo apoptosis by fisetin and hesperetin were
collected by centrifugation at 180g for 10 min, which were
then lysed by 50 μl of chilled cell lysis buffer on ice for
10 min. The reaction cocktail including 50 μl of 2× reaction
buffer (containing 10 mM DTT), 50 μl of sample, and 5 μl of
DEVD-pNA substrate was prepared and then added to 96-
well plates, which was incubated for 2 h at 37 °C. Finally,
the plate was read under 405-nm wavelengths by an ELISA
reader. Total protein concentrations determined by the Brad-
ford method were used to normalize the absorbance values.
Cell cycle analysis by flow cytometry
dsDNA content and distribution of cell cycle phases are
determined by flow cytometry. Briefly, 5×105 cells/well
were treated with increasing concentrations of fisetin and
hesperetin for 72 h. Then, the cells collected by centrifuga-
tion at 260g for 10 min were homogenized with 1 ml cold
PBS and fixed with 4 ml of cold ethanol overnight at
−20 °C for the analysis. The cells were centrifuged at
260g for 10 min, and pellets were homogenized with 1 ml
cold PBS and centrifugation was repeated. Afterwards, cell
pellets were homogenized with 1 ml PBS containing 0.1 %
Triton X-100, and then 100 μl RNase A (200 μg/ml) was
added and incubated at 37 °C for 30 min. One hundred
microliters of PI (1 mg/ml) was added to the cells, which
were incubated at room temperature for 15 min, and then
analyzed by flow cytometry.
Microarray analysis
Total RNAwas isolated from HL60 cells treated with fisetin
(20 and 50 μM) and hesperetin (100 and 150 μM) for 72 h
using Nucleospin Total RNA isolation kit (Machery-Nagel,
USA) according to the manufacturer’s instructions. Only
the RNA samples with an A260/A280 ratio between 1.9
and 2.1 were considered for further use. Expression profil-
ing is accomplished using the Illumina Human HT-12v4
beadchip microarrays (containing ∼47,000 transcripts:
∼30,000 genes) (Illumina, Inc., San Diego, CA). Initially,
500 ng of total RNA converted to cDNA, followed by
in vitro transcription to generate biotin-labeled cRNA using
the Illumina Total Prep RNA Amplification Kit (Ambion,
USA) based on the manufacturer’s instructions for hybrid-
ization analysis. Then, 1.5 μg of labeled cRNAwas hybrid-
ized to each array according to the Illumina whole-genome
gene expression direct hybridization assay protocol. Then,
arrays were imaged using the Illumina BeadArray Reader
to measure fluorescence intensity at each probe. The images
were processed and converted into signal intensities using
the Illumina GenomeStudio software (Illumina, Inc.). Gene
ontology and pathway analyses were performed to consider
the biological meaning of differential expression of genes
between the treated and untreated samples by using the
Kyoto Encyclopedia of Genes and Genomes (KEGG) and
Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Red-
wood City, CA).
Statistical analysis
Statistical significance was determined using one-way analy-
sis of variance (ANOVA) for MTT analyses and two-way
ANOVA for annexin V, MMP, caspase-3 activity, and cell
cycle analyses. P<0.05 was considered to be significant. All
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experiments were repeated in triplicate. Hierarchical cluster
analysis (Illumina Genome Studio) applied to data sets to
evaluate the Bproximity^ between genes and hierarchical clus-
ters was constructed with the statistically significant (P<0.05)
genes. Genes were considered differentially expressed when
logarithmic gene expression ratios in three independent hy-
bridizations were more than 1.5 or less than 0.66 and when
the P values were less than 0.05. For each comparison, we
obtained the list of differentially expressed genes constrained
by P value <0.05 and at least 2.0 fold change.
Results
The growth inhibitory effects of fisetin and hesperetin
on HL60 cells
To characterize the effects of fisetin and hesperetin on
HL60 cells’ growth, the viability of the cells treated with
agents (1–200 μM) for 48 and 72 h was measured using an
MTT assay. Results showed that fisetin was effective in
inhibiting the growth in a dose- and time-dependent man-
ner, whereas hesperetin showed significant effect on the
proliferation of the cells in a dose-dependent way especial-
ly after 72 h of incubation. For 48 h of hesperetin treat-
ment, growth inhibition was not significant up to 100 μM.
IC50 (inhibition of cell viability by 50 % at a particular
concentration) values at 48 and 72 h were calculated from
cell proliferation plots and were found to be 82 and 45 μM
for fisetin (Fig. 1a) and 190 and 142 μM for hesperetin,
respectively (Fig. 1b).
Fisetin and hesperetin trigger apoptosis in HL60 cells
HL60 cells were incubated with increasing concentrations
of fisetin and hesperetin for 72 h, and fisetin- and
hesperetin-induced changes in apoptosis (late apoptotic
plus early apoptotic population) were detected by flow cy-
tometry using annexin V-FITC and propidium iodide (PI)
staining. Figure 2 shows the fold changes in the percentage
of apoptotic HL60 cells as compared to untreated controls.
Fisetin treatment resulted in 1.6-, 6.2-, and 11.6-fold in-
creases in apoptosis in response to 20, 50, and 100 μM
fisetin, respectively (Fig. 2a). On the other hand, there
were 1.2-, 2.1-, and 3.3-fold increases in response to 50,
100, and 200 μM hesperetin, respectively (Fig. 2c).
Figure 2b, d indicates flow data representing the percent-
age of the cells in each flow quadrant. Fisetin was found to
be the most effective flavonoid for the induction of apo-
ptosis in HL60 cells based on the detection of PS on the
outer membrane.
Fisetin and hesperetin induce loss of mitochondrial
membrane potential in HL60 cells in a dose-dependent
manner
Loss of mitochondrial membrane potential is an important
sign of apoptosis since it has been linked to initiation and
activation of apoptotic cascades [18]. Therefore, it was deter-
mined whether these flavonoids cause the loss of MMP in
APL cells exposed to increasing concentrations of them by
using a JC-1 dye-based method. Treatment of HL60 cells with
20, 50, and 100 μM fisetin caused 1.01-, 1.15-, and 1.37-fold
increases in loss of MMP, respectively (Fig. 3a). Figure 3b
shows that hesperetin treatment resulted in 1.9-, 2.4-, and
5.4-fold increases in response to 50, 100, and 200 μM,
respectively.
Fisetin and hesperetin increase caspase-3 activity in HL60
cells
To determine whether apoptosis induced by fisetin and
hesperetin was associated with activation of caspase-3, a hall-
mark of apoptosis, the cells were treated with increasing con-
centrations of these agents for 72 h and the changes in
a
b
Fig. 1 Antiproliferative effects of fisetin (a) and hesperetin (b) on HL60
cells by the MTT assay. The IC50 values were calculated from cell
proliferation plots. The results, the means of three independent
experiments, are presented as mean±SEM; when not seen, they are
smaller than the thickness of the lines on the graphs. Statistical
significance was determined using one-way analysis of variance and
P<0.05 was considered to be significant
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caspase-3 enzyme activity were detected through the cleavage
of the labeled substrate DEVD-pNA. As indicated in Fig. 4a,
there were 1.05-, 2.0-, and 2.2-fold increases in caspase-3
activity of fisetin-treated HL60 cells in response to 20, 50,
and 100 μM, respectively, as compared to untreated controls.
On the other hand, treatment of HL60 cells with 50, 100, and
200 μM hesperetin caused 1.08-, 1.1-, and 2.8-fold increases
in caspase-3 enzyme activity, respectively (Fig. 4b).
Fisetin arrested cell cycle at the G2/M phase
while hesperetin at both G0/G1 and G2/M in HL60 cells
In order to determine the possible mechanism of antiprolifer-
ative activity of the agents, cell cycle profiles of APL cells in
response to 72 h of exposure to fisetin and hesperetin were
examined by flow cytometry in the presence of DNase-free
RNase and PI dye. Treatment of HL60 cells with fisetin re-
sulted in dose-dependent increases in the percentage of cells in
the G2/M phase, which was accompanied by a reduction in
the percentage of cells in the G0/G1 phase. The G2/M phase
cell cycle distribution was 0.89, 8, and 29.5 % at 20-, 50-, and
100-μM concentrations of fisetin, respectively (control value
0.57%) (Fig. 5a). On the other hand, hesperetin treatment was
found to result in a dose-dependent increase of cell population
in the G2/M phase. The G2/M phase cell cycle distribution
was 1.64, 3.65, and 13 % at 50-, 100-, and 200-μM concen-
trations of hesperetin, respectively (control value 0.46 %).
Moreover, the percentage of the cells in the G0/G1 phase
was found to increase especially at 100 (34.8 %) and 200
(44.3 %)μM hesperetin as compared to control (31.13 %)
while there was a dose-dependent decrease in the S phase
population (Fig. 5b).
Microarray analysis detects differentially expressed genes
affected by fisetin and hesperetin in HL60 cells
We examined the changes in expression levels of the genes
following treatment of HL60 cells with 20 and 50 μM fisetin
and 100 and 150 μM hesperetin. Isolated total RNAwas am-
plified and converted to biotin-labeled cRNA, which was hy-
bridized to a microarray system containing approximately 30,
000 genes. Hierarchical clustering of gene expression in un-
treated (control), fisetin-treated, and hesperetin-treated HL60
cells is shown in Fig. 6.
c
d
a
b
Fig. 2 Apoptotic effects of fisetin (a, b) and hesperetin (c, d) on HL60
cells by FACS analysis via annexin V-FITC/PI staining.Cells in the lower
right quadrant indicate annexin-positive/PI-negative (Q4), early
apoptotic cells. Cells in the upper right quadrant indicate annexin-
positive/PI-positive, late apoptotic (Q2) (b, d). The results, the means of
three independent experiments, are presented as mean±SEM; when not
seen, they are smaller than the thickness of the lines on the graphs.
Statistical significance was determined using two-way analysis of
variance and P<0.05 was considered to be significant
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A total of 54 and 1608 genes were significantly regulated
(P<0.05) in 20- and 50-μM-fisetin-treated HL60 cells, re-
spectively. The number of genes upregulated was 30 whereas
that of genes downregulated was 24 in 20-μM-fisetin-treated
HL60 cells. In 50-μM-fisetin-treated HL60 cells, 527 genes
were upregulated and 1081 genes were downregulated. Fold
change analysis displayed that TXNIP (thioredoxin-
interacting protein), TFPI (tissue factor pathway inhibitor),
miRNA1974, ID1 and ID3 (inhibitor of DNA binding 1 and
3), HSPA1B (heat shock protein 1B), and IDH1 (isocitrate
dehydrogenase 1, NADP+) were altered genes in both 20-
and 50-μM-fisetin-treated HL60 cells (Table 1). It was clear
thatMAP3K1 (mitogen-activated protein kinase kinase kinase
1), caspase-4, LASS6 (longevity assurance gene 6), and
CBLB (E3 ubiquitin-protein ligase CBL-B) were the examples
of upregulated genes, while LONP1 (Lon protease 1), STAT5A
and STAT3 (signal transducer and activator of transcription 5A
and 3), and JAK1 (Janus kinase 1) were some of the downreg-
ulated genes in 50-μM-fisetin-treated HL60 cells (Table 1).
On the other hand, a total of 130 and 691 genes were
significantly altered (P<0.05) in 100- and 150-μM-
hesperetin-treated HL60 cells, respectively. Treatment with
100 μM hesperetin resulted in the upregulation of 36 genes
and downregulation of 94 genes. The number of genes upreg-
ulated was 288, whereas that of genes downregulated was 403
in 150-μM-hesperetin-treated HL60 cells. SASH1 (SAM and
SH3 domain-containing protein 1), MT1F (metallothionein
1F), and SPRR2D (small proline-rich protein 2D) were repre-
sentative common upregulated genes, while TUBB1 (tubulin
beta-1 chain), ID3, ID1, NMU (neuromedin U), FGFR3 (fi-
broblast growth factor receptor 3), and S100P (calcium-
binding protein P) were common downregulated genes in both
100- and 150-μM-hesperetin-treated HL60 cells (Table 2)
based on fold change analysis. Furthermore, 150 μM
hesperetin induced more genes that were either upregulated
or downregulated as compared to 100 μM hesperetin
(Table 2). TXNIP, MT1A (metallothionein 1A), MAP3K1,
and SPRR2F (small proline-rich protein 2F) were some of
the upregulated genes, while RPS25 (ribosomal protein
S25), C-MYC, and tubulin family members (TUBA1C and
TUBB2C) were examples of downregulated genes (Table 2).
a
b
Fig. 3 Changes in MMP of HL60 cells treated with increasing
concentrations of fisetin (a) and hesperetin (b). The results, the means
of three independent experiments, are presented as mean±SEM; when
not seen, they are smaller than the thickness of the lines on the graphs.
Statistical significance was determined using two-way analysis of
variance and P<0.05 was considered to be significant
a
b
Fig. 4 Changes in caspase-3 enzyme activity in response to fisetin and
hesperetin in HL60 cells. The results, the means of three independent
experiments, are presented as mean±SEM; when not seen, they are
smaller than the thickness of the lines on the graphs. Statistical
significance was determined using two-way analysis of variance and
P<0.05 was considered to be significant
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Genetic networks affected by fisetin and hesperetin
in HL60 cells
To examine the affected genetic networks after fisetin and
hesperetin treatment, we carried out pathway analysis using
the IPA tool. These networks describe functional relationships
between gene products based on known interactions in the
literature. The results showed that the MAPK signaling path-
way, ID signaling pathway, cell cycle pathway, JAK/STAT
signaling pathway, cell cycle checkpoint pathways, and
PI3K/AKT signaling pathways were examples of the most
altered networks in fisetin-treated HL60 cells (Table 3).
Based on the data obtained from the IPA analysis, the ID
signaling pathway, eukaryotic ribosome and translation-
related networks, gluconeogenesis-related and mitosis-
related networks, and TGF-β and MAPK pathways were the
affected signaling networks in hesperetin-treated HL60 cells
(Table 4).
Discussion
APL accounts for 10 % of AML. It evolves very rapidly and
causes sudden hemorrhages; thus, it is extremely malignant
[1]. Currently, the treatment for APL includes chemotherapy,
ATRA, ATO, monoclonal antibodies, and hematopoietic stem
cell transplantation [2]. Harmful side effects, high recurrence
rate and development of resistance to chemotherapeutics and
other agents, and heterogeneity in APL cases make APL treat-
ment difficult; thus, they remain incurable in most cases [3].
Thus, new compounds treating APL are urgently needed to be
developed.
Flavonoids are known to block the initiation, promotion,
and progression of cancer by modulating various signaling
pathways that have significant roles in cell proliferation, dif-
ferentiation, apoptosis, angiogenesis, andmetastasis [5]. Thus,
flavonoids (both natural and synthetic analogs) are being in-
vestigated for their potentials in cancer therapy. Fisetin and
hesperetin, plant-derived flavonoids, have been shown to pro-
duce a wide range of pharmacological effects including anti-
oxidant, anti-inflammatory, and anticancer effects and found
to induce apoptosis in various tumor cells by causing alter-
ations in various cellular processes [7, 13]. The potential an-
ticarcinogenic effects of fisetin and hesperetin, naturally oc-
curring flavonoids, have been considered in various cancer
types especially solid tumors including lung, colon, and breast
cancers through several different mechanisms [11, 12, 16, 17].
However, to our knowledge, there is no detailed study inves-
tigating their mechanisms of action in APL.
In this study, we measured the time- and dose-dependent
effects of fisetin and hesperetin on APL cell viability using the
MTT assay. As indicated in the BResults^ section, the growth
of APL cells was inhibited by fisetin in a dose- and time-
dependent way while hesperetin wasmost effective in a longer
incubation time. The evaluation of changes in MMP and
caspase-3 enzyme activity showed that fisetin and hesperetin
treatment results in increases in the loss of MMP and caspase-
3 enzyme activity with different extents. Induction of apopto-
sis was also confirmed by localization of phosphatidylserine
to the outer membrane after treatment by flow cytometry. We
detected increased percentage of cells undergoing apoptosis in
a dose-dependent manner for both flavonoids. Therefore, we
display that fisetin and hesperetin not only inhibit the prolif-
eration but also induce the apoptosis of APL cells in vitro via
mitochondrial membrane depolarization and increased
caspase-3 enzyme activity, which suggested that they may
have potential to treat APL.
The results of our study are in accordance with the data in
the literature derived from various cancer types treated with
fisetin. For instance, in LNCaP prostate cancer cells, fisetin-
mediated apoptosis was related to activation of caspase cas-
cade [19]. In a recent study, Kang et al. [20] displayed that
fisetin had a dose-dependent cytotoxic effect on NCI-H460
human non-small cell lung cancer cells, and apoptosis induc-
tion in these cells was related to mitochondrial membrane
depolarization and caspase-3 activation. Fisetin was also re-
sponsible for growth inhibition of U266 multiple myeloma
cells via caspase-3 activation [21]. Similarly, hesperetin was
displayed to trigger cytotoxicity in MCF-7 breast cancer cells
a
b
Fig. 5 Effects of fisetin (a) and hesperetin (b) on cell cycle progression
of HL60 cells after treatment. The results, the means of three independent
experiments, are presented as mean±SEM; when not seen, they are
smaller than the thickness of the lines on the graphs. Statistical
significance was determined using two-way analysis of variance and
P<0.05 was considered to be significant
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via phosphatidylserine externalization and MMP loss [22]. In
another study, SiHa cervical cancer cells treated with
hesperetin underwent apoptosis evidenced by disruption of
MMP and caspase-3 activation [23].
It is very well known that the cell cycle plays a critical role
in cell proliferation, growth, and division [24], and cell cycle
arrest could be a reason for growth inhibitory effects of fisetin
and hesperetin. Therefore, we evaluated cell cycle distribution
of APL cells after fisetin and hesperetin treatment as com-
pared to untreated control cells. Our study shows that fisetin
and hesperetin treatment leads to G2/M arrest. The cell cycle
progression was also arrested at the G0/G1 phase at 100 and
200 μM hesperetin. Previous studies demonstrated that fisetin
and hesperetin inhibited the proliferation of cancer cells by
inducing G2/M or G0/G1 arrest. For instance, fisetin induced
G2/M arrest in human epidermoid carcinoma A431 cells [25],
Fig. 6 Hierarchical clustering
based on gene expression data
from HL60 cells exposed to
fisetin (upper panel) and
hesperetin (lower panel)
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HT-29 colon cancer cells [8], and PC3 prostate cancer cells
[26]. Human cervical SiHa cells treated with hesperetin
displayed G2/M arrest in a dose-dependent manner as well
[23]. Fisetin and hesperetin blocked cell cycle progression at
G0/G1 in T24 and E7 bladder and MCF-7 breast cancer cells
by decreasing cyclin-dependent kinases and cyclins involved
in the regulation of G0/G1 passage [27, 17]. Therefore, our
data together with literature knowledge explain that these two
flavonoids may arrest cell cycle in a cell-type-specific manner
and, thus, act as a non-specific cell cycle blocker.
We also performed genome-wide gene profiling analysis to
establish genes affected in response to fisetin and hesperetin.
Tables 1 and 2 summarize differentially expressed genes
constrained by P value <0.05 and at least 2.0 fold change.
As clearly seen in Table 1, TXNIP, miRNA1974, and TFPI
genes were common upregulated genes, which are known to
be involved in the inhibition of cell growth, invasion, and
metastasis. For instance, TXNIP or thioredoxin-interacting
protein plays a crucial role in apoptosis. Its expression was
found to be downregulated in many tumor cells [28], and
overexpression of TXNIP inhibits cancer cell growth [29].
Another upregulated gene, TFPI, an inhibitor of plasmin-
activating matrix metalloproteinases, blocks invasion and me-
tastasis [30]. Downregulation of some common genes such as
ID1, ID3, and IDH1 in fisetin-treated HL60 cells could be
responsible for its apoptotic effects as well. In a recent study,
suppression of ID1 and ID3, transcription regulators involved
in proliferation and apoptosis, was related to reduced tumor
growth [31, 32]. Downregulation of IDH1 after fisetin treat-
ment might cause cell death due to the accumulation of reac-
tive oxygen species (ROS) that damage proteins, lipids, and
DNA in the cells, since it is involved in the production of
NADPH required to scavenge ROS [33]. It is also understood
from Table 1 that additional genes encoding proteins with
significant functions in important cancer-related signaling
pathways such as the MAPK pathway (MKNK2, MAP2K5),
PI3K pathway (PIK3CB, GAB2), and JAK/STAT pathway
(STAT5A, STAT3, and JAK1) were downregulated in re-
sponse to higher fisetin concentration, thus leading to suppres-
sion of leukemic cell growth and induction of apoptosis.
LONP1 gene expression was significantly downregulated at
higher fisetin concentration, and it could be also an important
Table 1 The list of genes altered
≥2-fold after fisetin treatment of
HL60 cells together with their key
roles (italic type represents
upregulated genes)
Altered genes in fisetin-treated
HL60 cells
Fold change Function
20 μM 50 μM
TXNIP 11.76 12.61 Apoptosis, tumor suppressor
miRNA1974 2.496 4.23 Inhibits cell growth
TFPI 2.055 3.680 Inhibitor of invasion and metastasis
ID3 −7.798 −8.667 Dominant negative regulator of basic
helix-loop-helix transcription regulators
ID1 −3.685 −7.005 Dominant negative regulator of basic
helix-loop-helix transcription regulators
HSPA1B −3.313 −3.305 Heath shock response
IDH1 −2.685 −5.940 Cytosolic enzyme
Altered genes in 50-μM-fisetin-
treated HL60 cells
Fold change Function
MAP3K1 3.310 Apoptosis, caspase-3 substrate
CBLB 3.121 E3 ubiquitin ligase, autophagy
LASS6 2.728 Ceramide synthase, apoptosis
Caspase-4 2.422 Apoptosis
LONP1 −6.017 Tumor bioenergetic
STAT5A −3.604 Cell proliferation
PHB2 −3.582 Cell survival through the Ras pathway
XRCC6 −3.325 DNA repair
PIM2 −2.960 Kinase in cell survival
PRKCB −2.920 Protumorigenic
MKNK2 −2.883 MAP kinase pathway
MAP2K5 −2.477 MAP kinase pathway
PIK3CB −2.445 PI3 kinase pathway, cell proliferation
CHECK2 −2.382 Cell cycle
STAT3 −2.390 Cell proliferation
GAB2 −2.168 PI3 kinase pathway, cell proliferation
JAK1 −2.045 Cell proliferation
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Table 2 The list of genes altered
≥2-fold after hesperetin treatment
of HL60 cells including their
functions in the cell (italic type
represents upregulated genes)
Altered genes in hesperetin-treated
HL60 cells
Fold change Function
100 μM 150 μM
SPRR2D 4.574 5.985 Differentiation
MT1F 2.758 4.851 Tumor suppressor
SASH1 2.508 3.023 Tumor suppressor
S100P −8.285 −10.153 Cell proliferation
ID1 −5.467 −6.361 Dominant negative regulator of basic
helix-loop-helix transcription regulators
NMU −5.062 −6.065 Invasion, metastasis
ID3 −3.913 −4.256 Dominant negative regulator of basic
helix-loop-helix transcription regulators
FGFR3 −3.270 −3.623 Cell proliferation
TUBB1 −3.010 −3.327 Cell division, tubulin isotype
Altered genes in 150-μM-
hesperetin-treated HL60 cells
Fold change Function
TXNIP 2.977 Apoptosis, tumor suppressor
MT1G 2.939 Tumor suppressor
TPM1 2.734 Tropomyosin 1, tumor suppressor
SPRR2F 2.673 Differentiation
RERG 2.629 Ras-related growth inhibitor
ST7 2.609 Tumor suppressor, cell cycle arrest
MAP3K1 2.606 Apoptosis, caspase-3 substrate
RASA1 2.438 Inhibitor of mitogenic signal
MT1A 2.434 Tumor suppressor
SIN3A 2.400 Tumor suppressor
RPS25 −8.177 Ribosome component
TUBA1C −3.544 Cell division, tubulin isotype
EEF1A1 −3.042 Protein translation
RPS6P1 −3.029 Ribosome component
PRKCB1 −2.432 Cell proliferation
C-MYC −2.157 Proto-oncogene transcription factor
PIM1 −2.330 Proto-oncogene kinase
TUBB2C −2.226 Cell division
RPS9 −2.208 Ribosome component
PCK2 −2.206 Enzyme involved in gluconeogenesis
RXRA −2.122 Differentiation
Table 3 Affected networks in fisetin-treated HL60 cells by IPA
analysis (italic type represents networks modulated in both 20- and 50-
μM fisetin treatment)
Network/pathway P value
MAPK signaling pathway (50 μM) 0.04
ID signaling pathway 2.71E−05 (20 μM)
3.62E−04 (50 μM)
Nucleotide excision repair (50 μM) 1.48E−06
Cell cycle pathway (50 μM) 2.47E−05
JAK/STAT signaling pathway (50 μM) 0.002
Protein folding 0.01 (20 μM)
2.01E−09 (50 μM)
Cell cycle checkpoint pathways (50 μM) 2.57E−04
PI3K/AKT pathway (50 μM) 0.04
Table 4 Affected networks in hesperetin-treated HL60 cells by IPA
analysis (italic type represents networks modulated in both 100- and
150-μM hesperetin treatment)
Network/pathway P value
ID signaling pathway 4.52E−04 (100 μM)
0.008 (150 μM)
TGF-β pathway 7.45E−04 (100 μM)
3.32E−04 (150 μM)
Cytoplasmic ribosomal components (150 μM) 1.27E−10
Translation factors (150 μM) 4.24E−06
Gluconeogenesis (150 μM) 4.29E−04
Mitosis (150 μM) 0.001
MAPK signaling pathway (150 μM) 0.01
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target to induce leukemic cell death because this gene is found
to be overexpressed in different tumors and cell lines [34].
The genome-wide changes in the expression levels of
genes after hesperetin treatment in HL60 APL cells are sum-
marized in Table 2. SPRR2D, MT1F, and SASH1 were up-
regulated genes that are known to play roles in cell prolifera-
tion, apoptosis, and differentiation. It is known that cancer
cells have no or lower expression of SPRRs compared to
normal cells [35]. Therefore, increased expression of
SPRR2D is thought to induce cell growth suppression with
an unknown mechanism.MT1F, a member of the metallothio-
nein family, is expressed transiently in response to stimulation
and plays an important role in cell growth by modulating gene
transcription [36]. In a recent study, exogenous overexpres-
sion of the MT1F gene increased apoptosis in colon cancer
cells [37], which supports our data. SASH1, a potential tumor
suppressor, may function in various signaling pathways due to
its SH3 and SAM domains; thus, its downregulation is related
to tumor growth [38]. Therefore, its increased expression after
hesperetin treatment might induce apoptosis and growth sup-
pression. Similar to fisetin treatment as discussed above, ID1
and ID3 genes were downregulated in hesperetin treatment,
thus inducing apoptosis. The other common downregulated
gene was NMU, which was found to be increased in AML
cells, and its knockdown caused growth arrest [39]. Therefore,
it may be a reason for hesperetin-related antiproliferative ef-
fect. Another significantly downregulated gene was S100P,
whose upregulation results in increased cell proliferation in
several tumors such as endometrial cancer and oral squamous
cell carcinoma [40, 41]. As well as these common altered
genes, higher hesperetin treatment also induced either up- or
downregulation of several genes as indicated in Table 2. It is
interpreted from Table 2 that increased hesperetin concentra-
tion resulted in downregulation of additional tubulin-encoding
genes, TUBB2C and TUBA1A, which could cause problems
in cell division and then induce apoptosis [42]. Hesperetin
impaired protein synthesis by targeting cytoplasmic ribosomal
proteins such as RPS6P1, RPS9, and RPS25 and factors in-
volved in translation initiation like EEF1A1. Another impor-
tant downregulated gene was C-MYC which is described as a
proto-oncogenic transcription factor and upregulated in vari-
ous cancer types such as leukemia, lung, and breast cancers,
thus inducing cell proliferation and inhibition of apoptosis via
altering the expression of several target genes [43]. Therefore,
its downregulation by hesperetin could be a strategy to inhibit
HL60 cell growth. PIM1, a member of serine/threonine ki-
nases involved in cell survival and proliferation, is
overexpressed in a variety of cancer types such as leukemias,
lymphomas, and pancreatic and prostate cancers [44]. It is also
known that PIM1 functions together with C-MYC to induce
malignancy. In our study, hesperetin downregulates both C-
MYC and PIM1, therefore inducing significant growth inhi-
bition and apoptosis.
We also characterize differentially modulated networks in
response to fisetin and hesperetin using the IPA tool. Genes
associated with biological functions are taken into consider-
ation for analysis to identify networks, showing physical or
functional relationships among differentially expressed genes.
As clearly seen in Table 3, IPA analysis of fisetin-induced
pathways includes ID signaling, JAK/STAT, and MAPK ki-
nase signaling pathways. On the other hand, Table 4 displays
networks/pathways modulated after hesperetin treatment,
which include networks involved in protein synthesis (cyto-
plasmic ribosomal components, translation factors) and cell
division. All these data are consistent with gene expression
profiles.
Conclusions
The present study has revealed that fisetin and hesperetin have
significant antiproliferative effects on HL60 APL cells evi-
denced by induction of apoptosis and cell cycle arrest. Based
on the data presented, fisetin and hesperetin trigger apoptosis
and growth suppression via affecting various significant tar-
gets as in HL60 cells, and these new targets could open the
usage of new strategies together with fisetin and hesperetin to
overcome difficulties in APL treatment. These data also pro-
vide significant insights about the mechanisms of action of
fisetin and hesperetin in HL60 cells for the first time. Further
in vivo investigations are needed to confirm its antitumor ac-
tivity and toxicity profiles.
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